Last updated: February 25, 2026
What is NDC 65862-0474?
NDC 65862-0474 corresponds to the drug Apremilast (Otezla), marketed by Amgen. It is an oral medication approved for the treatment of psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease.
Market Size and Growth
1. Market Overview
- Global psoriasis treatment market was valued at approximately $11.5 billion in 2022. It is projected to grow at a CAGR of 9.5% through 2030.[1]
- Psoriatic arthritis (PsA) market is estimated near $2.4 billion globally, with a CAGR of 7% from 2022 to 2030.[2]
- Oral ulcer management market remains niche, with a limited number of approved oral systemic options like Apremilast.
2. Market Penetration of Apremilast
- As of 2022, over 1.8 million patients had been prescribed Apremilast globally.[3]
- U.S. market share: Estimated at 25-30% among biologic and non-biologic oral treatments for psoriasis and PsA.[4]
- Key competitors include biologics such as adalimumab, etanercept, and newer small molecules like risankizumab.
3. Geographic Breakdown
| Region |
Market Size (2022) |
Expected CAGR (2022-2030) |
Key Factors |
| North America |
$4.2 billion |
8.8% |
High prevalence, strong reimbursement |
| Europe |
$3.1 billion |
9.2% |
Extensive biologic approvals |
| Asia-Pacific |
$2.4 billion |
11% |
Emerging markets, rising disease awareness |
| Rest of World |
$1.8 billion |
10% |
Increasing healthcare expenditure |
Pricing Dynamics
1. Current Pricing
- Average wholesale price (AWP): Approximately $2,500 per month per patient in the U.S. (list price).[5]
- Net price: Approximately $1,800 after rebates and discounts.
- Weekly cost: Around $575 based on a 4-week month.
- Annual treatment cost: Approximately $21,900.[6]
2. Reimbursement and Payer Dynamics
- Fully covered under insurance plans, including Medicare and private insurers.
- High out-of-pocket costs for uninsured patients.
- Managed care organizations favor cost-effective treatments, influencing overall pricing strategies.
3. Price Trends and Influences
- Price has remained stable since FDA approval in 2014, with slight reductions due to rebates.
- Newer formulations or biosimilars could exert downward pressure.
- Price elasticity in North America flexible due to high disease prevalence and treatment switching.
Price Projections (2023-2030)
| Year |
Estimated Monthly Price |
Comments |
| 2023 |
$2,500 |
Stable, rebates persist |
| 2025 |
$2,350 |
Slight reduction expected from rebates and discounts |
| 2027 |
$2,200 |
Market saturation, biosimilar competition begins |
| 2030 |
$2,000 |
Further competition, patent expiry considerations |
Note: Price adjustments depend on regulatory changes, biosimilar entry, and payer negotiations.
Regulatory and Patent Landscape
- Patent expiry: Expected around 2028-2030 in major markets; biosimilar and generic competition possible.[7]
- Orphan drug status: Not applicable, limiting exclusivity extensions.
- Regulatory pathways: Submission for new indications ongoing, could influence pricing if approved for more indications.
Competitive Landscape
| Competitors |
Product |
Approval Year |
Market Share (2022) |
Price Comparison |
| AbbVie |
Humira |
2002 |
35% |
~$2,600/month in US |
| Pfizer |
Xeljanz |
2012 |
10% |
~$1,800/month |
| Novartis |
Cosentyx |
2015 |
20% |
~$2,900/month |
Biosimilar Impact
- Biosimilars for biologics are progressing, but no biosimilar in the small-molecule space for Apremilast.
- Competition from biologics and small molecules will influence pricing strategies.
Key Takeaways
- The global market for psoriasis and psoriatic arthritis treatments projects steady growth, with Apremilast maintaining a substantial share.
- Current U.S. list price averages $2,500/month with expected gradual reductions to ~$2,000/month by 2030 due to market competition.
- Reimbursement policies, biosimilar entry, and patent expiries will influence future pricing and market share.
- Though costly, Apremilast remains a preferred oral agent due to ease of use and safety profile.
FAQs
Q1: Will Apremilast's price decrease significantly after patent expiry?
A1: Yes, biosimilar and generic competition typically drive prices downward, potentially reducing costs by 20-40%.
Q2: How does Apremilast compare with biologic treatments in pricing?
A2: It is less expensive than many biologics, which often cost over $3,000/month, but prices converge when factoring in rebates and discounts.
Q3: Are there emerging therapies that threaten Apremilast's market share?
A3: Yes, newer small molecules and biosimilars aim to capture market share, potentially impacting Apremilast pricing and volume.
Q4: What is the key driver for Apremilast's market growth?
A4: Increasing prevalence of psoriasis and PsA, patient preference for oral therapies, and expanding indications.
Q5: How do payer policies influence Apremilast's market penetration?
A5: Insurance coverage and reimbursement levels directly impact prescribing patterns and patient access.
References
[1] Grand View Research. (2022). Psoriasis treatment market size.
[2] Fortune Business Insights. (2022). Psoriatic arthritis market forecast.
[3] Amgen. (2022). Otezla global sales report.
[4] IQVIA. (2022). U.S. psoriasis market share analysis.
[5] Red Book. (2022). Average wholesale price lists.
[6] CMS. (2022). Reimbursement data for psoriasis treatments.
[7] FDA. (2022). Patent expiration timelines for Otezla.
